1. Market Research
  2. > Biotechnology Market Trends
  3. > ACT Biotech, Inc. - Product Pipeline Review - 2013

ACT Biotech, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

ACT Biotech, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “ACT Biotech, Inc. - Product Pipeline Review - 2013” provides data on the ACT Biotech, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, ACT Biotech, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from ACT Biotech, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- ACT Biotech, Inc. - Brief ACT Biotech, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of ACT Biotech, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of ACT Biotech, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the ACT Biotech, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate ACT Biotech, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of ACT Biotech, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the ACT Biotech, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with ACT Biotech, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of ACT Biotech, Inc. and identify potential opportunities in those areas.

Table Of Contents

ACT Biotech, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
ACT Biotech, Inc. Snapshot 4
ACT Biotech, Inc. Overview 4
Key Information 4
Key Facts 4
ACT Biotech, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
ACT Biotech, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
ACT Biotech, Inc. - Pipeline Products Glance 9
ACT Biotech, Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
ACT Biotech, Inc. - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
ACT Biotech, Inc. - Drug Profiles 12
ACTB-1003 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
ACTB-1010 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
ACTB-1011 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
telatinib 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
ACT Biotech, Inc. - Pipeline Analysis 17
ACT Biotech, Inc. - Pipeline Products by Therapeutic Class 17
ACT Biotech, Inc. - Pipeline Products by Route of Administration 18
ACT Biotech, Inc. - Pipeline Products By Mechanism of Action 19
ACT Biotech, Inc. - Recent Pipeline Updates 21
ACT Biotech, Inc. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables


ACT Biotech, Inc., Key Information 4
ACT Biotech, Inc., Key Facts 4
ACT Biotech, Inc. - Pipeline by Indication, 2013 6
ACT Biotech, Inc. - Pipeline by Stage of Development, 2013 7
ACT Biotech, Inc. - Monotherapy Products in Pipeline, 2013 8
ACT Biotech, Inc. - Phase II, 2013 9
ACT Biotech, Inc. - Phase I, 2013 10
ACT Biotech, Inc. - Pre-Clinical, 2013 11
ACT Biotech, Inc. - Pipeline By Therapeutic Class, 2013 17
ACT Biotech, Inc. - Pipeline By Route of Administration, 2013 18
ACT Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 20
ACT Biotech, Inc. - Recent Pipeline Updates, 2013 21

List of Figures


ACT Biotech, Inc. - Pipeline by Indication, 2013 6
ACT Biotech, Inc. - Pipeline by Stage of Development, 2013 7
ACT Biotech, Inc. - Monotherapy Products in Pipeline, 2013 8
ACT Biotech, Inc. - Pipeline By Therapeutic Class, 2013 17
ACT Biotech, Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Glycoprotein 41 (gp41) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Glycoprotein 41 (gp41) - Pipeline Review, H2 2016’, provides in depth analysis on Glycoprotein 41 (gp41) targeted ...

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cellular Tumor Antigen p53 (Tumor Suppresso ...

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Telomerase ...

Tetanus - Pipeline Review, H2 2016

September 2016 $ 2000

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.